/https://media.cnbc.com/dims/origin/108343257/Spider-Man-Brand-New-Day.jpg "Spider-Man Smashes Box Office Records with ‘Brand New Day’ Preview Haul")
Morgan Stanley is advising investors to target quality stocks with dividend payouts as the market enters a mid-cycle transition phase. Strategists highlight that growth will increasingly depend on AI adoption. Key picks include Coca-Cola, Colgate-Palmolive, SLB, and Gilead Sciences, all noted for their strong fundamentals and income potential.
As the market navigates a dynamic phase, Morgan Stanley recommends investors focus on high-quality stocks, many of which also offer attractive dividend yields. The firm identifies this period as a "classic mid-cycle transition," where growth drivers are shifting from early-cycle operating leverage to the increasing adoption of Artificial Intelligence.
Mike Wilson, Morgan Stanley's chief U.S. equity strategist, noted in a recent memo that while near-term consolidation or further downside is possible, the overall trend favors quality. "The quality rotation should ultimately support index resilience and even broad participation, albeit with different leadership," he stated.
Morgan Stanley's strategy favors companies with high free-cash-flow yields, stable earnings per share, robust balance sheets, and strong profit margins. The firm's research team has screened for these "quality names" that they rate as overweight, with a particular focus on those that also provide income through dividends. Among the highlighted stocks are:
- Coca-Cola (KO): With a dividend yield of 2.41%, Coca-Cola saw its shares surge over 4% following a strong second-quarter earnings report where it beat expectations and raised its full-year outlook. Morgan Stanley reiterated its "overweight" rating, citing long-term organic sales growth reinforced by positive short-term developments and competitive advantages. The stock has gained 26% year-to-date.
- Colgate-Palmolive (CL): This consumer staples company, yielding 2.26%, is set to report its second-quarter earnings soon. Morgan Stanley maintains an "overweight" rating and considers it a top pick, anticipating potential for multiple expansion beyond its solid year-to-date performance, with shares up approximately 18% so far in 2026.
- SLB (SLB): The oilfield services giant has gained 31% year-to-date and recently posted better-than-expected second-quarter earnings and revenue. Strong offshore drilling activity and demand for production solutions helped offset disruptions. SLB offers a dividend yield of 2.35%.
- Gilead Sciences (GILD): Morgan Stanley expects Gilead's HIV-prevention shot, Yeztugo, to achieve $1.1 billion in sales for 2026, surpassing consensus estimates. The biopharmaceutical company, with a 2.43% dividend yield, has seen its stock price rise nearly 10% this year and is due to release its latest results shortly.
These selections underscore Morgan Stanley's thesis that quality and income generation can coexist, offering investors a resilient approach in the current market environment.
